Actavis has elected Michael R Gallagher and Peter J McDonnell to its board of directors.
Both Gallagher and McDonnell are former members of the board of directors for Allergan, whom Actavis completed its acquisition of this week.
Brent Saunders, CEO and president and Actavis, commented: “The addition of Michael and Peter brings significant experience from Allergan to our board and I welcome their insights and expertise as we combine our two dynamic organisations.
“I want to thank the entire Allergan board for their stewardship to Allergan shareholders in building a strong and successful company.”
Gallagher was elected to the Allergan board in 1998 and served as its lead independent director and chair of the organisation and compensation committee.
In 2004, he retired as CEO and director of Playtex products where he joined in 1995. Prior to this, he held a number of senior roles at companies including Procter & Gamble and Reckitt & Colman.
McDonnell was appointed to the Allergan board in 2013 and served on the corporate governance and compliance committee and the science and technology committee.
He has served as the chief medical editor of Ophthalmology Times and his research interests include the causes and correction of refractive error, corneal wound healing and microbial keratitis.